Clinical & Scientific

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A new partnership between a Chinese biotech and a Brazilian public institute aims to slash the $500k cost of CAR-T therapy, making it accessible to all.

Jetstream Venture Fund's deals with Surf Therapeutics and Hill Research signal a new era of accessible venture capital backing transformative technologies.

China's Gan & Lee partners with JW Pharmaceutical to launch its novel bi-weekly GLP-1 drug, Bofanglutide, into the competitive South Korean market.

Following a massive stock surge, Forte Biosciences is raising $150M. The funds are crucial for a pivotal year of clinical trials for its autoimmune drug.

Rune Labs launches StrivePD Guardian, an AI companion using Anthropic's Claude and a massive dataset to offer 24/7 personalized support for patients.

With a $137M war chest, Sidewinder Therapeutics is advancing a new class of ultra-precise cancer drugs aimed at tumors that have long evaded treatment.

Century Health and VCU are building a massive AI-driven database to decode steatotic liver disease, a silent epidemic affecting nearly 2 billion people.

With a new patent for its drug ALPHA-1062, Alpha Cognition may become a first-mover in the $14 billion traumatic brain injury market, which has no approved therapies.

In a tough biotech market, NewcelX's $1.35M financing at a 30% premium signals strong confidence in its pioneering stem cell therapy for Type 1 Diabetes.

As China surpasses the US in key research metrics, a new English platform aims to bridge the information gap for global scientists and innovators.

With improved financials and progress on therapies for cannabis use disorder and Down syndrome, the French biotech charts a confident course for the future.

After a major capital overhaul, PAVmed pivots to growth, advancing cancer diagnostics, remote monitoring, and a relaunched device portfolio.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

A promising oral therapy for a rare, aggressive lung cancer is now under review in Europe, offering a new option for patients with limited treatments.

Early trial data for tazbentetol shows promise in treating schizophrenia by rebuilding synapses, a potential paradigm shift in psychiatric medicine.

A new 750-patient clinical trial is underway to provide definitive evidence for advanced thrombectomy, potentially changing how deadly blood clots are treated.

In a strategic play, VIVUS is slashing the price of its oral obesity drug QSIVA, challenging the dominance of costly new injectables like Wegovy.

Biolojic Design's adaptive AI drug for asthma and eczema hits a key milestone with Teva, heralding a new era for personalized autoimmune treatment.

A new alliance between Discovery Life Sciences and Mindpeak aims to solve inconsistent biomarker interpretation, a critical bottleneck in cancer drug development.